Showing 5821-5830 of 8715 results for "".
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Adelle Walker Joins DermTech as VP of Consumer Productshttps://practicaldermatology.com/news/adelle-walker-joins-dermtech-as-vp-of-consumer-products/2461088/Adelle Walker is now Vice President of Consumer Products at DermTech. Inc. as the company continues its investment in bringing its precision genomics platform to the skin health and wellness categories. Ms. Walker brings more than 20 years of experience to
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric
- AbbVie, University of Toronto Establish Endowed Chair in Ethnodermatologyhttps://practicaldermatology.com/news/abbvie-university-of-toronto-establish-endowed-chair-in-ethnodermatology/2461081/AbbVie donated CDN $3M to establish an AbbVie Chair in Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine. One of the first positions of its kind in the world, the Chair will drive collaborative academic research, provide advanc
- Acne Breakthrough: Fat Cells in the Skin May Help Fight Acnehttps://practicaldermatology.com/news/fat-cells-in-the-skin-may-help-fight-acne/2461080/New research suggests that fibroblasts outside of hair follicles play a larger role in acne development. Fibroblasts produce an antimicrobial peptide called cathelicidin in skin. To counter an infection within a hair follicle, the surrounding skin undergoes a process called reactiv
- Study: More Than Half of Postmenopausal Women Experience Female Pattern Hair Losshttps://practicaldermatology.com/news/study-more-than-half-of-postmenopausal-women-experience-female-pattern-hair-loss/2461079/More than half of postmenopausal women experience female pattern hair loss, according to a studypublished online in Menopause. In a new cross-sectional study involving 178 women seen at a menopause clinic, researchers aimed to evaluate the prevalence of female pat
- Third Harmonic Bio Launches with an Eye on Chronic Urticariahttps://practicaldermatology.com/news/third-harmonic-bio-launches-with-an-eye-on-chronic-urticaria/2461078/Third Harmonic Bio is launching with the close of a Series B financing campaign. With total capital to date of $155 million, the company plans to fund development of its lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria. 
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- GW Dermatology, La Roche-Posay Establish GW Skin Cancer Research Acceleration Fundhttps://practicaldermatology.com/news/gw-dermatology-la-roche-posay-establish-gw-skin-cancer-research-acceleration-fund/2461074/The Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) has partnered with La Roche-Posay to establish the La Roche-Posay Skin Cancer Research Acceleration Fund at GW. The $50,000 gift will be used to support the growth
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in